- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07528469
The Effects of PeptiStrong and Whey on Muscle Function In Older Adults
The Effects of PeptiStrong and Low Dose Whey Protein Versus High Dose Whey Protein Alone on Muscle Function In Older Adults
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The aim of this study is to compare two protein drinks containing whey protein (derived from milk) in healthy adults aged 60 to 85 years. One group will consume a standard whey protein drink (20g), while the other group will consume a drink with half the total protein dose (10g) made of whey protein and PeptiStrong, a fava bean hydrolysate containing bioactive peptides.
The study will assess whether the lower protein drink containing PeptiStrong will lead to equal or greater improvements than the standard drink in physical function, such as the ability to stand up from a chair, walk at a normal pace, maintain balance, and grip strength. The study will also examine markers related to inflammation, fatigue, and quality of life.
The intended value of this research is to improve understanding of how targeted nutritional strategies may help maintain or improve muscle function in older adults. The findings may help inform future nutritional recommendations and the development of practical dietary interventions aimed at supporting healthy ageing and independence.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Niamh Mohan, PhD
- Phone Number: +353 1 430 1290
- Email: mohan.niamh@nuritas.com
Study Locations
-
-
-
Liverpool, United Kingdom, L3 3AF
- Recruiting
- LJMU, Byrom Street
-
Contact:
- Graeme Close, Prof.
- Phone Number: 0151 231 2121
- Email: g.l.close@ljmu.ac.uk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Men and women aged 60 to 85 years at the time of enrolment
- Community-dwelling (living independently or with minimal assistance)
- Able to walk independently (with or without a walking aid) and complete simple physical function tests (such as standing up from a chair and walking short distances)
- Willing and able to attend two study visits at the research facility (baseline and end of study)
- Willing and able to consume a protein drink containing whey protein (derived from milk) once daily for 30 days
- Able to understand the study information and provide written informed consent
Exclusion Criteria:
- Any known food allergy or intolerance to fava bean protein or milk protein
- Diagnosed kidney disease or any medical condition where increased protein intake is contraindicated
- Yes to any of the answers on the "Older Adult Functional Assessment Screening Questionnaire"
- Individuals with implanted electronic devices
- Current or recent (within the past 3 months) participation in another clinical research study involving a nutritional or exercise intervention
- Conditions that significantly impair mobility or balance such that safe completion of the physical function tests is not possible
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: PeptiStrong + whey protein
2.4g PeptiStrong (provides 1.6g protein) + 8.4g of whey protein = 10g total protein
|
Fava bean protein hydrolysate containing bioactive peptides mixed with whey protein as dry powder for drinkable protein shake
|
|
Active Comparator: Whey protein
20g whey protein
|
Whey protein as dry powder for drinkable protein shake
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hand Grip Strength via hand held dynamometer
Time Frame: Baseline to Week 4
|
Change from baseline to end of study in grip strength as assessed via hand held dynamometer
|
Baseline to Week 4
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Chair Stand Test - Part of short performance physical battery
Time Frame: Baseline to week 4
|
Change from baseline to end of study in physical function assessment via chair stands.
This test measures the time taken to complete 5 sit-to-stand repetitions in seconds.
A lower time (fewer seconds) = better performance.
As part of the full short performance physical battery it is converted to a subscore of 0-4, where a higher score = better performance
|
Baseline to week 4
|
|
Gait Speed as part of short performance physical battery
Time Frame: Baseline to week 4
|
Change from baseline to end of study in physical function assessment assessed as time to walk a fixed distance in seconds and reporting in meters per second.
Higher speeds indicate better performance.
This is converted to a subscore of 0-4 within the full short performance physical battery
|
Baseline to week 4
|
|
6 Minute Walking Endurance Test
Time Frame: Baseline to week 4
|
Change from baseline to end of study in physical function and endurance assessed as the total distance walked in 6 minutes in meters.
A greater distance reflects better walking endurance and functional capacity.
|
Baseline to week 4
|
|
Balance test as part of short performance physical battery
Time Frame: Baseline to week 4
|
Change from baseline to end of study in balance as assessed by the ability to hold three standing positions of increasing difficulty: side-by-side, semi-tandem, and tandem stance in seconds.
Higher scores indicate better balance.
The overall score is converted to a a sub-score of 0-4 within the full short performance physical battery.
|
Baseline to week 4
|
|
Balance assessment via force plates
Time Frame: Baseline to week 4
|
Change from baseline to end of study in balance as assessed via force plates
|
Baseline to week 4
|
|
Quality of Life via the Sarcopenia Quality of Life (SarQoL®) Questionnaire
Time Frame: Baseline to week 4
|
Change from baseline to end of study in quality of life as measured via subjective SarQOL questionnaire.
The total score ranges from 0 to 100, with higher scores reflecting a higher quality of life.
|
Baseline to week 4
|
|
Fatigue via Multidimensional Fatigue Inventory Questionnaire
Time Frame: Baseline to week 4
|
Change from baseline to end of study in self-reported fatigue as assessed via multidimensional fatigue inventory questionnaire.
This 20-item questionnaire covers five dimensions: General Fatigue, Physical Fatigue, Mental Fatigue, Reduced Motivation, and Reduced Activity.
Each subscale score ranges from 4 to 20, with higher scores indicating greater fatigue
|
Baseline to week 4
|
|
C-reactive protein (CRP) via blood test
Time Frame: Baseline to week 4
|
Change from baseline to the end of study in inflammatory marker C-reactive protein (CRP) in serum as mg/L
|
Baseline to week 4
|
|
Interleukins via blood test
Time Frame: Baseline to week 4
|
Change from baseline to the end of study in Interleukin inflammatory markers in serum as pg/mL
|
Baseline to week 4
|
|
Body composition: Muscle mass and body fat via bioelectrical impedance analysis
Time Frame: Baseline to week 4
|
Change from baseline to end of study in muscle mass and body fat as measured by bioelectrical impedance analysis in kilograms and % of total body weight
|
Baseline to week 4
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Graeme Close, Professor, Liverpool John Moore University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PEPVFH+60/26
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Protein Supplementation
-
Eisenhower Army Medical CenterMedical Nutrition USA, Inc.CompletedProtein Supplementation
-
Alexandria UniversityCompletedProtein SupplementationEgypt
-
Bettery S.A.CompletedProtein SupplementationPortugal
-
Cardinal Tien HospitalCompletedProtein Supplementation | Exercise InterventionTaiwan
-
University of AarhusCompleted
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São Paulo; Coordenação de Aperfeiçoamento... and other collaboratorsCompletedProtein Supplementation | Sports NutritionBrazil
-
Poznan University of Physical EducationPoznan University of Medical Sciences; National Science Centre, Poland; Faculty... and other collaboratorsCompletedSupplementation | Sport | Sports Nutrition | Sports Dietetics | Protein Kinases | Aerobic Capacity | Fat Free MassCzechia, Poland
-
University of CadizCompletedPlacebo | Cold-water Immersion | Protein-carbohydrates Supplementation | Active RecoverySpain
-
Universidad Católica San Antonio de MurciaCompleted
-
California Baptist UniversityCompletedDietary SupplementationUnited States
Clinical Trials on PeptiStrong + whey protein
-
The University of Texas Medical Branch, GalvestonMeiji Co., Ltd.Completed
-
McMaster UniversityCanadian Institutes of Health Research (CIHR); University of California, Davis and other collaboratorsCompletedRegulation of Muscle Protein SynthesisCanada
-
Sports Performance and Applied Research in Trials...RecruitingRecovery | Muscle Strength | Sports Nutritional Sciences | Supplements | Muscle Strength RecoveryUnited Kingdom
-
Efforia, IncActive, not recruiting
-
Musclegen Research, Inc.CompletedAbsorption; Disorder, Protein | Analysis, Event History
-
University of NottinghamCompletedAssessing the Impact of "Super-whey" vs. Isonitrogenous Whey on Muscle Protein Synthesis (ARLA-WHEY)SarcopeniaUnited Kingdom
-
University of ReginaIovate Health Sciences International IncRecruiting
-
Skidmore CollegeCompletedObesity | OverweightUnited States
-
Wenshan City People's HospitalNot yet recruitingIschemic Stroke | Traumatic Brain Injury | Neurocritical Conditions
-
Peking Union Medical College HospitalNot yet recruiting